Mitsubishi UFJ Asset Management Co. Ltd. Has $21.60 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 511,983 shares of the company’s stock after selling 6,744 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.13% of Moderna worth $21,595,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Venturi Wealth Management LLC raised its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the 4th quarter worth $37,000. Crowley Wealth Management Inc. acquired a new position in Moderna during the 4th quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on MRNA. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Berenberg Bank boosted their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Evercore ISI set a $50.00 target price on shares of Moderna in a research note on Friday, February 14th. Finally, Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Stock Performance

MRNA stock opened at $31.12 on Monday. The company has a market capitalization of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The business has a 50-day simple moving average of $34.72 and a two-hundred day simple moving average of $44.13.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.